Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant announced a deal on Monday to license a Phase 1 candidate called OLX75016 from ...

Twenty-two state attorneys general sued the Trump administration on Monday in a bid to halt a new cap on indirect costs for ...

Several brand-name drugmakers believe they will withstand any drug pricing impacts from President Donald Trump’s tariffs — ...

Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl commercial touting cheaper versions of brand-name ...

Boehringer Ingelheim said its experimental treatment for a chronic lung disease succeeded in a pivotal study, and it's taking ...

Roivant ends namilumab program, Bio-Thera partners on golimumab biosimilar, Caliway advances fat treatment, Orca Bio's T cell success, funding for Alterity & Ascentage ...

Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company.

China blacklists Illumina amid tensions with the US, threatening its market access, while US actions limit Chinese rival MGI; ...

Sens. Dick Durbin (D-IL) and Roger Marshall (R-KS) are calling on the FDA to take action against a Super Bowl ad coming on ...

Sanofi, AstraZeneca and two leading trade groups want clarity around an appellate decision that called for Teva to delist ...